Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 10/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4537742 | 0.82 | DUT (0.49) | DUTALDH1A1LMNAPKMCRBN | |
| SCHEMBL9891077 | 0.79 | DUT (0.54) | DUTALDH1A1LMNAPKMCRBN | |
| SCHEMBL15798508 | 0.79 | DUT (0.54) | DUTALDH1A1LMNAPKMCRBN | |
| SCHEMBL12955007 | 0.79 | DUT (0.54) | DUTALDH1A1LMNAPKMCRBN | |
| SCHEMBL15798507 | 0.79 | DUT (0.54) | DUTALDH1A1LMNAPKMCRBN | |
| SCHEMBL4348697 | 0.79 | L3MBTL1 (0.59) | DUTALDH1A1LMNAPKMCRBN | |
| SCHEMBL6102943 | 0.77 | CRBN (0.56) | DUTALDH1A1LMNAPKMCRBN | |
| SCHEMBL1923335 | 0.75 | PKM (0.61) | DUTALDH1A1LMNAPKMCRBN | |
| SCHEMBL8377765 | 0.75 | PKM (0.51) | DUTALDH1A1LMNAPKMCRBN | |
| SCHEMBL4372127 | 0.75 | PKM (0.51) | DUTALDH1A1LMNAPKMCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | claimed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | claimed |
| EP-4688781-A1 | METHODS AND REAGENTS FOR SYNTHESIZING HALOALDEHYDES, AND USES THEREOF | Simon Fraser University (CA) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201390-A1 | METHODS AND REAGENTS FOR SYNTHESIZING HALOALDEHYDES, AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2024-10-03 | — | — | WO | disclosed |
| US-20230129710-A1 | Methods and Reagents for Synthesizing Nucleosides and Analogues Thereof | SIMON FRASER UNIVERSITY (CA) | 2023-04-27 | — | — | US | disclosed |
| US-20230129710-A1 | Methods and Reagents for Synthesizing Nucleosides and Analogues Thereof | SIMON FRASER UNIVERSITY (CA) | 2023-04-27 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-114746099-A | Eukaryotic semisynthetic organisms | 斯克利普斯研究所 | 2022-07-12 | — | — | CN | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| WO-2021191830-A1 | METHODS AND REAGENTS FOR SYNTHESIZING NUCLEOSIDES AND ANALOGUES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2021-09-30 | — | — | WO | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-3172211-B1 | TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-07-03 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129710-A1 | Methods and Reagents for Synthesizing Nucleosides and Analogues Thereof | NUDT1, ADAR, APRT | DUT 20/4885ALDH1A1 55/4885LMNA 1420/4885 |
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | DUT 4425/4885ALDH1A1 3412/4885LMNA 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.